Search

Displaying results 8811 - 8820 of 10000 in total
  1. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous le...

  2. Drug

    Rasburicase

    go.drugbank.com/drugs/DB00049
    ApprovedInvestigational

    Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

  3. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. … Recombinant Batroxobin in relatively affordable and could be accessed by mass production.

    International brands: Su Ling, Ba Qu Ting
  4. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].

  5. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

  6. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.

  7. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  8. Drug

    Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

    go.drugbank.com/drugs/DB15813
    Investigational

    Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  9. Drug

    Delavirdine

    go.drugbank.com/drugs/DB00705
    ApprovedInvestigationalWithdrawn

    A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

    Synonyms: (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide), 2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
  10. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells,...